AG-SILDENAFIL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

SILDENAFIL (SILDENAFIL CITRATE)

Prieinama:

ANGITA PHARMA INC.

ATC kodas:

G04BE03

INN (Tarptautinis Pavadinimas):

SILDENAFIL

Dozė:

50MG

Vaisto forma:

TABLET

Sudėtis:

SILDENAFIL (SILDENAFIL CITRATE) 50MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

4

Recepto tipas:

Prescription

Gydymo sritis:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0136261002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2022-11-15

Prekės savybės

_Pr_
_AG-SILDENAFIL_
_Page 1 of 43_
PRODUCT MONOGRAPH
PR
AG-SILDENAFIL
sildenafil (as sildenafil citrate) tablets
25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
Date of Revision:
August 28, 2018
Angita Pharma Inc.
1310 Nobel Street
Boucherville, Quebec
J4B 5H3
SUBMISSION CONTROL NO.: 214622
_Pr_
_AG-SILDENAFIL_
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................
3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS......................................................................................................
3
WARNINGS AND
PRECAUTIONS....................................................................................
4
ADVERSE
REACTIONS......................................................................................................
7
DRUG INTERACTIONS
.....................................................................................................
11
DOSAGEAND
ADMINISTRATION...................................................................................
14
OVERDOSAGE
....................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
................................................................
16
STORAGE AND
STABILITY..............................................................................................
19
SPECIAL HANDLING
INSTRUCTIONS...........................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................
19
PART II: SCIENTIFIC INFORMATION
............................................................................
20
PHARMACEUTICAL
INFORMATION......................................................